Cardiovascular safety of long-term anti-obesity drugs in subjects with overweight or obesity: a systematic review and meta-analysis.
Purpose: Anti-obesity therapy can reduce body weight; however, it is not clear whether it can reduce major adverse cardiovascular events (MACEs). We conducted a systematic review and meta-analysis to assess the effect of long-term anti-obesity drugs on MACEs in individuals with overweight or obesity...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 77; no. 11; pp. 1611 - 1622 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research systematic review tables/charts Journal Article |
| Publicado: |
Springer Nature
Nov2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=153123998&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 153123998 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00316970 NP9 jtl: European Journal of Clinical Pharmacology issn: 00316970 maglogo: N pubinfo: dt: Nov2021 vid: 77 iid: 11 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 153123998 150536957 153123998 153123998 10.1007/s00228-021-03160-7 153123998 ppf: 1611 ppct: 11 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Cardiovascular safety of long-term anti-obesity drugs in subjects with overweight or obesity: a systematic review and meta-analysis. aug: au: Zhang, Lin Liu, Zhi Liao, Shenling He, He Zhang, Mei affil: Department of General Practice, West China Hospital, Sichuan University, 610041, Chengdu, Sichuan, China sug: subj: Obesity Drug Therapy Cardiovascular System Drug Effects Antiobesity Agents Patient Safety Human Systematic Review Meta Analysis Medline Embase Cochrane Library Cardiometabolic Risk Factors ab: Purpose: Anti-obesity therapy can reduce body weight; however, it is not clear whether it can reduce major adverse cardiovascular events (MACEs). We conducted a systematic review and meta-analysis to assess the effect of long-term anti-obesity drugs on MACEs in individuals with overweight or obesity. Methods: The MEDLINE, Embase, and Cochrane Library databases and clinical trial registries (https://clinicaltrials.gov) were searched up to 3 May 2021 for randomized controlled trials (RCT) that compared anti-obesity drugs with controls and reported cardiovascular events in subjects with overweight or obesity. Heterogeneity was described by the I2 value. The Mantel–Haenszel randomized effects model was adopted to calculate risk ratios (RR) and weighted mean differences (WMD). Sensitivity analysis was used to assess the stability of the effects. Publication bias was assessed by Begg's funnel plot and Egger's test. The Cochrane Collaboration risk-of-bias tool was used to evaluate the bias of each included RCT. Results: Twelve articles were included; 21,391 and 17,618 subjects were in the anti-obesity drug and placebo groups, respectively. There was no difference in MACEs between the anti-obesity drug and placebo groups (RR 0.99; 95% CI: 0.88–1.12). Compared with placebo, anti-obesity interventions reduced body weight (WMD: − 3.96 kg; 95% CI: − 4.89, − 3.03) and improved lipid and blood glucose profiles. The intervention also did not increase the incidence of depression or anxiety or the risk of suicidal ideation. Conclusion: Long-term anti-obesity drugs did not show a benefit in lowering MACEs in overweight or obese subjects, although the drugs resulted in a decrease in body weight and improved cardiometabolic parameters. pubtype: Academic Journal doctype: meta analysis research systematic review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|